Ikena Oncology to Participate in November 2021 Virtual Investor Conferences
Ikena Oncology (Nasdaq: IKNA) announced its participation in several virtual investor conferences during November 2021. Key events include:
- BMO Biopharma Spotlight Series on November 8, 2021, focusing on targeted therapies.
- Credit Suisse 30th Annual Healthcare Conference on November 11, 2021, featuring a fireside chat.
- Stifel 2021 Virtual Healthcare Conference on November 15, 2021, with corporate presentations.
- Jefferies London Healthcare Conference on November 18, 2021, offering pre-recorded content.
Webcasts will be available for replay on the company's website.
- None.
- None.
BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that management will participate in several virtual investor conferences in November 2021.
Details are as follows:
Conference: BMO Biopharma Spotlight Series: Emerging Trends and Therapeutics in Oncology
Panel; Emerging Trends in Oncology: Targeted Therapies and Other Novel Treatment Modalities
Date: Monday, November 8, 2021, 3:25pm EST; available for replay following the event
Conference: Credit Suisse 30th Annual Healthcare Conference
Fireside Chat; Investor Meetings
Date: Thursday, November 11, 2021, 3:30pm EST; live and available for replay
Webcast Link
Conference: Stifel 2021 Virtual Healthcare Conference
Corporate Presentation; Investor Meetings
Date: Monday, November 15, 2021, 11:20am EST; live and available for replay
Webcast Link
Conference: Jefferies London Healthcare Conference
Corporate Presentation; Investor Meetings
Date: Thursday, November 18, 2021, 8:00am GMT; pre-recorded and available for replay
Webcast Link
The presentation webcasts can be accessed by visiting the Investors & Media section of the company’s website at www.ikenaoncology.com. The webcast will be archived for a period of 90 days following the conclusion of the live event.
About Ikena Oncology
Ikena Oncology is focused on developing novel therapies targeting key signaling pathways that drive the formation and spread of cancer. The Company’s lead targeted oncology program, IK-930, is a TEAD inhibitor addressing the Hippo signaling pathway, a known tumor suppressor pathway that also drives resistance to multiple targeted therapies. Additional programs include an ERK5 inhibitor program targeting the KRAS signaling pathway and programs targeting the tumor microenvironment and immune signals, two of which are being developed in collaboration with Bristol Myers Squibb, including IK-175, an aryl hydrocarbon receptor antagonist designed to modulate the tumor microenvironment. Ikena’s pipeline is built on addressing genetically defined or biomarker-driven cancers and developing therapies that can serve specific patient populations in need of new therapeutic options. To learn more, visit www.ikenaoncology.com or follow us on Twitter and LinkedIn.
Media Contact:
Gwen Schanker
LifeSci Communications
gschanker@lifescicomms.com
Investor Contact:
Rebecca Cohen
Ikena Oncology
rcohen@ikenaoncology.com
FAQ
What conferences will Ikena Oncology participate in November 2021?
When is Ikena's presentation at the BMO Biopharma Spotlight Series?
Where can I access Ikena's conference webcasts?
What is the date for the Credit Suisse Healthcare Conference for Ikena?
When will Ikena present at the Stifel Virtual Healthcare Conference?
Is there a replay available for the Jefferies London Healthcare Conference?
